Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Germany

Research and Innovation Action · Running

REPhRAME REcurrent urinary tract infection: Efficacy and safety of PHage theRapy and Microbiota transfEr

Coordinator
Johann Wolfgang Goethe-Universitaet Frankfurt Am Main, Germany
Runs
1 June 2026 to 31 May 2031
Status
Running
EU funding
€15.2m
Total cost
—
Partners
16 organisations in 8 countries
Type
Research and Innovation Action
Grant agreement
101287159

What the project is doing

In the project's own words, from its summary on CORDIS.

Recurrent urinary tract infections (rUTIs) impose a substantial clinical and socio-economic burden, particularly in women, and are increasingly complicated by antimicrobial resistance (AMR). Current treatment options rely heavily on antibiotics, fueling resistance and limiting therapeutic efficacy. The REPhRAME project addresses this unmet need by evaluating innovative, non-antibiotic strategies: a bacteriophage-based investigational medicinal product for acute treatment, and fecal microbiota transplantation (FMT-IMP) to prevent recurrence.

Building on a seamless Phase Ib/IIa randomized controlled trial, the study will determine optimal routes of administration, assess efficacy in reducing antibiotic use, and evaluate recurrence prevention. Multi-omics analyses, biomarker discovery, and health economic modelling complement the clinical trial, while patient engagement, ethical oversight, and regulatory alignment ensure societal relevance and translational impact.

By integrating precision medicine, novel biologics manufacturing, and robust clinical evidence, REPhRAME aims to pioneer sustainable alternatives to antibiotics, improving quality of life and supporting EU goals in AMR mitigation and healthcare innovation.

Topics

Who is involved

OrganisationCityCountryRole
Johann Wolfgang Goethe-Universitaet Frankfurt Am MainFrankfurt Am MainGermanyCoordinator
Sib Swiss Institute of BioinformaticsGenfSwitzerlandParticipant
Universitaet BernBernSwitzerlandParticipant
Universitat ZurichZurichSwitzerlandParticipant
Deutsches Zentrum Fur Infektionsforschung (dzif) eVBraunschweigGermanyParticipant
Fraunhofer Gesellschaft Zur Forderung Der Angewandten Forschung eVMunchenGermanyParticipant
Klinikum Der Universitaet Zu KoelnKoelnGermanyParticipant
Linq Management GmbHBerlinGermanyParticipant
Medizinische Hochschule HannoverHannoverGermanyParticipant
Snipr Biome ApsCopenhagen ODenmarkParticipant
HUN-REN Szegedi Biologiai KutatokozpontSzegedHungaryParticipant
Rigas Stradina UniversitateRigaLatviaParticipant
Academisch Ziekenhuis LeidenLeidenNetherlandsParticipant
Jafral, Biotehnoloske Raziskave Inrazvoj, DooLjubljanaSloveniaParticipant
The University of ReadingReadingUnited KingdomParticipant
University of LeicesterLeicesterUnited KingdomParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI